Your browser doesn't support javascript.
loading
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis.
White, Eric M; Macy, Jonathan I; Bateman, Kirk M; Comstock, Timothy L.
Afiliación
  • White EM; Complete Family Vision Care, San Diego, CA, USA.
Curr Med Res Opin ; 24(1): 287-96, 2008 Jan.
Article en En | MEDLINE | ID: mdl-18062846
ABSTRACT

OBJECTIVE:

This study compared the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T; Zylet) with dexamethasone 0.1%/tobramycin 0.3% (DM/T; Tobradex) in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis. RESEARCH DESIGN AND

METHODS:

This was a multicenter, randomized, investigator-masked, parallel-group study. Subjects with clinically diagnosed blepharokeratocon-junctivitis in at least one eye were randomized to LE/T (n = 138) or DM/T (n = 138) administered four times per day, for 14 days. The primary efficacy endpoint was the change from baseline to Day 15 (+/- 1 day) in the signs and symptoms composite score using a non-inferiority metric to compare LE/T to DM/T. Safety endpoints included visual acuity (VA), biomicroscopy, intraocular pressure (IOP) assessments, and adverse events.

RESULTS:

At Day 15, the mean (SD) change from baseline in the signs and symptoms composite score was -15.2 (7.3) for LE/T-treated subjects and -15.6 (7.7) for DM/T-treated subjects. The upper bound of the 90% confidence interval for the difference in change from baseline was less than the non-inferiority margin not only at Day 15 but also at Day 7 and Day 3 for both the intent-to-treat and per protocol populations. Subjects treated with DM/T experienced a significant increase in IOP versus those treated with LE/T at Day 7, Day 15, and overall (mean [SD] of 0.6 [2.3] vs, -0.1 [2.2], p = 0.03, 1.0 [3.0] vs. -0.1 [2.4], p = 0.01, and 2.3 [2.3] vs. 1.6 [1.7], p = 0.02, respectively).

CONCLUSIONS:

LE/T satisfied the condition of non-inferiority to DM/T in decreasing the signs and symptoms of ocular inflammation associated with blepharokeratoconjunctivitis. Subjects treated with DM/T experienced more of an increase in IOP.

LIMITATION:

Although the single-masked design of this study could be considered a limitation, care was taken to ensure that the investigator was masked.
Asunto(s)
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Tobramicina / Blefaritis / Dexametasona / Androstadienos / Queratoconjuntivitis Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Curr Med Res Opin Año: 2008 Tipo del documento: Article País de afiliación: Estados Unidos
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Tobramicina / Blefaritis / Dexametasona / Androstadienos / Queratoconjuntivitis Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Curr Med Res Opin Año: 2008 Tipo del documento: Article País de afiliación: Estados Unidos